Objective: To investigate the adjuvant cabergoline therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia.
Materials and methods: This randomized clinical trial was done on 110 PCOS women with increased serum prolactin concentration [1.5 ford more than normal level (>37.5ng/ml)].Participants were divided into two groups: Case group (n=55) treated with metformin 1gr/day and cabergoline 0.5 mg/week for 4 months and control group (n=55) treated with metformin 1g/day and placebo weekly. Testosterone, prolactin, and DHEAS level were measured before and four months after intervention in two groups. Also, situation of menstrual cycles asked and recorded before and after intervention.
Inclusion criteria:110 PCOS women with increased serum prolactin concentration [1.5 ford more than normal level (>37.5ng/ml)], who referred to endocrinology clinic of Khatamal Anbiaa Cilinic, Shahid Sadoughi University of Medical Sciences, were examined for other causes of increased prolactin levels such as TSH test, hypophis MRI for detection of prolactinema and other disorders or tumors that can increase prolactin, and then women who had diagnosed as PCOS according to the latest AES standards enrolled in the study.
Exclusion criteria: Patients who had other endocrine disorders (such as thyroid disorders), history of cardiovascular disease, history of using the increasing prolactin drugs, women who wanted to be pregnant, and who couldn’t tolerate the cabergoline were excluded from the study.
Primary outcome measure: Menstrual irregularity, and laboratory findings (serum testosterone, DHEAS and prolactin).
Secondary outcome measure: Weight